Resume of Achievements

Key Account Management

Brand Management

Sales Management

Brand management

Transplantation

Dialysis

Infectious Diseases Immunology

Dermatology

Nephrology

Hepatitis

Brand Management (2002 – 2012) Launch excellence

• Certican Launch – Second to market (as Brand Manager) • Relaunch of Cubicin – Field restructure (as Marketing Manager)

0.0

3.0

6.0

9.0

Certican

Rapamune0

400

800

1,200

1,600

2,000

2,400

2,800

3,200

2008 2009 2010 2011 2012 (2013)

Cubicin

Re-launch

Brand Management (2002 – 2012) Life cycle management – Secondary markets

Psoriasis Eczema

Dermatology

Brand Management (2002 – 2012) Life cycle management

mio

Launch year: 1983

• Loss of exclusivity • PBS price increase • Secondary indications

Brand Management (2006 – 2012) Life cycle management - 9 years of 20% growth

mio

0%

10%

20%

30%

40%

Year 3 Year 4 Year 5 Year 6 Year 7 Year 8 Year 9

myfortic year on year % Growth

5-year CAGR at year 9 (2012) = 23%

Key account Management (2010 – 2012) Key account strategy

0.0

2.0

4.0

6.0

8.0

myfortic sales pre KAM

Key Account execution

0.0

1.0

2.0

3.0

4.0

5.0

6.0

7.0

Simulect(Novartis)

Zenapax(Roche)

Key account Management (2010 – 2012) High cost drug

• Unfunded, High cost drug • Top 3 spend in Transplanting hospitals

0%

10%

20%

30%

40%

50%

60%

20 14 9 7 4

L O E WITHIN PATENT

20+ *

Years post launch

Portfolio Management (2010 – 2012) 5 Year CAGR

50%

40%

30%

20%

10%

0%

* 2 year CAGR

Portfolio Management

Cellcept

Prograf

NEORAL

CERTICAN

RAPAMUNE

SIMULECT

Thymologuline

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

-20% -10% +0% +10% +20% +30% +40% +50%

Mar

ket

shar

e

MAT Growth

Australia

Europe

AMAC Region

Global

USA

Portfolio Management

Portfolio Market share Australia’s performance vs Global

2009 2010 2011 2012

Port

folio

Mar

ket

Sh

are

0%

2%

4%

6%

8%

10%

12%

Dec

-93

Feb

-94

Ap

r-9

4

Jun

-94

Aug

-94

Oct

-94

Dec

-94

Feb

-95

Ap

r-9

5

Jun

-95

Aug

-95

Oct

-95

Dec

-95

Feb

-96

Feb

-96

3

Queensland

Australia

Sales Management

4%

5%

6%

7%

8%

9%

10%

11%

Dec

-93

Jan-

94

Feb

-94

Mar

-94

Apr

-94

May

-94

Jun-

94

Jul-

94

Aug

-94

Sep

-94

Oct

-94

No

v-94

Dec

-94

Jan-

95

Feb

-95

Mar

-95

Apr

-95

May

-95

Jun-

95

Jul-

95

Aug

-95

Sep

-95

Oct

-95

No

v-95

Dec

-95

Jan-

96

Feb

-96

Mar

-96

Apr

-96

May

-96

ZESTRIL MonoprilPrinivil CoversilTritace Ramace

Dec

-93

Jan-

94

Feb

-94

Mar

-94

Apr

-94

May

-94

Jun-

94

Jul-

94

Aug

-94

Sep

-94

Oct

-94

No

v-94

Dec

-94

Jan-

95

Feb

-95

Mar

-95

Apr

-95

May

-95

Jun-

95

Jul-

95

Aug

-95

Sep

-95

Oct

-95

No

v-95

Dec

-95

Jan-

96

Feb

-96

Mar

-96

Apr

-96

May

-96

QUEENSLAND

Australia

State Sales Manager (1993-1996) Queensland team – Highest market share

• 6 new generation ACE-i • Queensland Zestril market share highest in country • Queensland Zestril market share tops all competitors

New generation ACE-i Market Share

0%

1%

2%

3%

QUEENSLAND AUSTRALIA

Market share 1 year post launch

State Sales Manager (1993-1996) Queensland team – Launch success

QUEENSLAND

State Sales Manager (1993-1996) Queensland team - Top hospital sales

0%

15%

30%

45%

QUEENSLAND VICTORIA N S W

% National Sales

QUEENSLAND

• Queensland market potential: 18.0% of National C/V sales • Queensland achieved 19.8% of National sales • Queensland achieved 49% of National Hospital sales

10%

14%

18%

YTD

%

Pre R.HUGGAN R.HUGGAN

Contract State Sales Manager (1997) Queensland – Market share growth

1996 1997

• Interim Manager - 12 month contract position

15%

18%

21%

24%

27%

Pre R.HUGGAN R.HUGGAN

1996 1997

Queensland share of National sales

State Sales Manager (1993-1996) Queensland – Post Loss of Exclusivity

$0.5 mio turn-over orders

75%

80%

85%

90%

95%

Tenormin Nolvadex Cardizem

Queensland Australia

• Turnover orders generated up to 50% State sales

$0

$100,000

$200,000

$300,000

$400,000

$500,000

$600,000

Jly

Au

g

Sep

Oct

Dec

Mar

May

Jly2

95% Brand Market Share

75%

80%

85%

90%

95%

100%

Dec

-91

Jan-

92

Feb-

92

Mar

-…

Ap

r-92

May

-…

Jun

-92

Jul-

92

Au

g-9

2

Sep

-92

Oct

-92

No

v-…

Dec

-92

Jan-

93

Feb-

93

Mar

-…

Ap

r-93

May

-…

Jun

-93

Jul-

93

Au

g-9

3

Sep

-93

Oct

-93

No

v-…

Dec

-93

Jan-

94

Feb-

94

Mar

-…

Ap

r-94

May

-…

Jun

-94

Jul-

94

Au

g-9

4

Sep

-94

Oct

-94

No

v-…

Dec

-94

Jan-

95

Feb-

95

Mar

-…

Ap

r-95

May

-…

Jun

-95

Jul-

95

Au

g-9

5

Sep

-95

Oct

-95

No

v-…

Dec

-95

Jan-

96

Feb-

96

Mar

-…

QUEENSLAND

Australia

State Market Share

Performance – post Loss of Exclusivity Tenormin (State) & Neoral (National)

0%

25%

50%

75%

100%

NEORAL

Cicloral

Cysporin

National Sales

Brand® share of generic molecule

0% 10% 20% 30% 40% 50% 60% 70%

Novartis

Roche

Wyeth

Janssen

Business Unit Management (2005-2009) The Leading Company In Therapeutic Area

Novartis

2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012

14.2% 10.3% 12.7% 8.8% 5.4% -2.8% -3.1% 23.8% 2.0% 2.9% 6.4% 3.0%

-5%

0%

5%

10%

15%

Sales to Budget 2001 – 2012 Sales exceeded budget 10/12 yrs

* *

* BU moved to Primary Care

-5%

“Your openness and willingness to challenge traditional beliefs and offer creative alternatives

has been refreshing.”

Key Opinion Leaders

“I have always had the highest respect for you and your approach in achieving the best outcome for patients first, but also maintaining the company's position in high regard. I must say that your qualities are very unique.” Head of Department “I have always been impressed by your power of reasoning and the respect you have amongst the transplantation community. I will also miss our discussions along the way that have always been full of substance..” Head of Department “…an excellent industry partner with a wealth of knowledge in the field of transplantation that was second to none. You are a true gentleman who puts evidence before corporate interests in dealing with professionals.” Head of Department “… respect for your ability to cut through the bullsh*t and work collaboratively with clinicians to advance transplantation medicine.” Head of Department “We always knew who we were dealing with while you were there. We were very fortunate to have had clear and open communication with you.” Head of Department “I appreciated the input you brought from industry in a constructive, professional manner striving to improve the care to this group of patients, often innovatively.” Head of Department “I have enjoyed our association as you were able to combine a professional approach with a good sense of humour. “ Head of Department

Peers “You are so approachable that it was always easy to pick up the phone & speak to you. It was very refreshing way to work.”

Global PM

“… working with you was always fun always new things to learn.”

Marketing Science

“It’s always been enjoyable working with you.”

Health Economics’

“Congratulations! The results for you are excellent and best in Specialty care.”

Specialty Care Director on coaching audit survey results

“Novartis is so much better for having had people like you and your contributions.”

Sales Manager

Sales team 360o feedback

“Amazing business acumen.”

“Robert is great at generating new and unique ideas.”

“...looks beyond the obvious and doesn't stop at the first answers.”

“He appropriately challenges the status quo.”

“...listens to their individual needs”.

“He is passionate about his work and this is very motivating.”

“His enthusiasm is contagious and motivates his team.”

“...not afraid to give difficult feedback and always does this in a very productive way.”

• 2012: ONE OF THE TOP 10% MOST

VIEWED LINKED-IN PROFILES

• 2014: INVITED TO PUBLISH ON LINKED-IN

Social Media (2012-2014)

BACK UP Robert Huggan A.B.N. 1168 2754 566 Email: Robert-Huggan@outlook.com Twitter: https://twitter.com/2010Robh Blog: http://2010robh.blogspot.com.au/ Linked-In: http://au.linkedin.com/pub/robert-huggan/24/9b9/793 One of the top 10% most viewed LinkedIn profiles for 2012.